Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.65 |
| ▸ | STS | P08842 | 1/20 | 0.58 |
| ▸ | PLAU | P00749 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3060994 | 0.92 | PLAU (0.60) | MAPTL3MBTL1SRD5A2STSPLAU | |
| SCHEMBL1879336 | 0.90 | NPC1 (0.55) | MAPTL3MBTL1SRD5A2STSPLAU | |
| SCHEMBL7129800 | 0.89 | MAPT (0.80) | MAPTL3MBTL1SRD5A2STSPLAU | |
| SCHEMBL24800 | 0.85 | MAPT (0.73) | MAPTL3MBTL1SRD5A2STSPLAU | |
| SCHEMBL16367718 | 0.84 | SRD5A2 (0.59) | MAPTL3MBTL1SRD5A2STSPLAU | |
| SCHEMBL5260372 | 0.83 | SRD5A2 (0.89) | MAPTL3MBTL1SRD5A2STSPLAU | |
| SCHEMBL8033816 | 0.83 | SRD5A2 (0.89) | MAPTL3MBTL1SRD5A2STSPLAU | |
| Water SCHEMBL9243001 | 0.83 | MAPT (0.70) | MAPTL3MBTL1SRD5A2STSPLAU | |
| SCHEMBL4282905 | 0.83 | MAPT (0.70) | MAPTL3MBTL1SRD5A2STSPLAU | |
| Water SCHEMBL20527670 | 0.83 | MAPT (0.70) | MAPTL3MBTL1SRD5A2STSPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116789605-A | Novel electron transport material based on benzo [ c ] cinnoline and preparation thereof | 四川大学 | 2023-09-22 | — | — | CN | disclosed |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20180110873-A1 | ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM | BRISTOL-MYERS SQUIBB COMPANY | 2018-04-26 | — | — | US | disclosed |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-15 | — | — | US | disclosed |
| US-20110319416-A1 | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions | EMORY UNIVERSITY (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319416-A1 | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions | EMORY UNIVERSITY (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2010088408-A2 | SUBUNIT SELECTIVE NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | EMORY UNIVERSITY (US) | 2010-08-05 | — | — | WO | disclosed |
| CN-1642580-B | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands | JANSSEN PHARMACEUTICA NV | 2010-05-26 | — | — | CN | disclosed |
| US-7629468-B2 | Neuroprotectants, analgesics or anticonvulsants | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-08 | — | — | US | disclosed |
| US-20040082592-A1 | Metabotropic glutamate receptor antagonists | JANSSEN-CILAG SA (FR) | 2004-04-29 | — | — | US | disclosed |
| WO-2003082350-A2 | RADIOLABELLED QUINOLINE AND QUINOLINONE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-09 | — | — | WO | disclosed |
| EP-1332133-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-08-06 | — | — | EP | disclosed |
| WO-2002028837-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-04-11 | — | — | WO | disclosed |
| EP-0562824-B1 | Thermal recording material | FUJI PHOTO FILM CO LTD (JP) | 1997-06-11 | — | — | EP | disclosed |
| US-5464804-A | Heat sensitive color layer with electron donor, colorless dye is black color aminofluoran, amino compound and isocyanate compound | FUJI PHOTO FILM CO., LTD. (JP) | 1995-11-07 | — | — | US | disclosed |
| US-5288688-A | Comprising electron-donating colorless dye, isocyanate and amino compounds; antifogging, discoloration inhibition, storage stability | FUJI PHOTO FILM CO., LTD. (JP) | 1994-02-22 | — | — | US | disclosed |
| EP-0562824-A2 | Thermal recording material | FUJI PHOTO FILM CO., LTD. (JP) | 1993-09-29 | — | — | EP | disclosed |
| WO-1992017516-A1 | PROCESS FOR CURING POLYQUINOLINE POLYMERS AND COMPOSITIONS THEREOF | MAXDEM INCORPORATED (US) | 1992-10-15 | — | — | WO | disclosed |
| CN-86105597-A | Make the method for novel pyrazoline compounds | — | 1987-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082592-A1 | Metabotropic glutamate receptor antagonists | GRM3, GRM1, GRIN3A | MAPT 3958/4885L3MBTL1 2214/4885SRD5A2 1043/4885 |
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | MAPT 2167/4885L3MBTL1 2131/4885SRD5A2 2715/4885 |
| US-20110319416-A1 | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions | GRIN1, GRIN2A, GRIN2B | MAPT 598/4885L3MBTL1 2410/4885SRD5A2 2959/4885 |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | MAPT 3403/4885L3MBTL1 2793/4885SRD5A2 4223/4885 |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | MAPT 3059/4885L3MBTL1 1464/4885SRD5A2 4572/4885 |
| US-20180110873-A1 | ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM | MKI67, HDGF, PCLAF | MAPT 3696/4885L3MBTL1 1994/4885SRD5A2 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.